Alamar Biosciences, Inc. will release its financial results for the second quarter of 2026 after market close on Monday, August 10, 2026. The announcement will provide insights into the company's performance for the quarter ending June 30, 2026. Following the release, company management will host a conference call to discuss the results.

The conference call is scheduled to begin at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. Investors can access the live audio webcast through the "Investors" section of the Alamar Biosciences website. The webcast will be archived and available for replay after the event for those unable to attend the live session.

Key Details

Alamar Biosciences is a commercial-stage proteomics company focused on advancing protein detection and analysis. The company leverages its proprietary NULISA™ technology and the ARGO™ HT System to enable high-sensitivity biomarker detection. This approach aims to support early disease detection and research across various disease states.

Investors and interested parties can visit the company's website for more information. The archived webcast will provide a convenient option for reviewing the discussion at a later time.

Alamar Biosciences, Inc. has partnered with leading research universities to launch a national-scale proteomics initiative aimed at accelerating biomarker discovery and validation for Alzheimer’s disease and related neurodegenerative conditions. The project will utilize Alamar’s NULISAseq Neuro 220 panel to generate large-scale plasma proteomic data from approximately 21,000 samples collected from 10,000 Alzheimer’s Disease Research Center (ADRC) participants across the United States. This initiative seeks to provide the research community with a deeply multiplexed, clinically anchored proteomic dataset to support discovery and translational research.

The project is co-led by professors Sarah Biber, PhD, at Washington University in St. Louis; Sterling Johnson, PhD, at the University of Wisconsin; and Tatiana Foroud, PhD, director of the National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD) at Indiana University. Samples are stored at NCRAD, which provides centralized national infrastructure for coordinated access and biomarker generation at scale. The initiative is part of the CLARiTI portfolio and leverages its infrastructure to support harmonized data workflows.

Profiling will employ Alamar’s NULISAseq Neuro 220 panel, enhanced with a newly added eMTBR-Tau assay. This assay enables simultaneous blood-based representation of tau tangle burden alongside a broad panel of neurodegeneration and neuroinflammation biomarkers. The panel offers the largest number of brain-derived Tau targets along with assays relevant to alpha-synuclein biology and other protein aggregation markers, facilitating the study of multiple neurodegenerative disease pathways within the same cohort.

A central goal of the project is the creation of an open, publicly accessible proteomic dataset linked to National Alzheimer’s Coordinating Center (NACC) IDs. This linkage allows researchers to connect new proteomic profiles with rich longitudinal data available through the ADRC Program, including clinical, cognitive, neuroimaging, genetic, genomic, fluid biomarker, and neuropathology data. AI and computational teams will apply multimodal approaches for disease classification, biomarker discovery, and prediction of disease progression.

The effort has been advanced through partnerships with the Alzheimer’s Association, the Robertson Foundation, an anonymous foundation, and the Alzheimer’s Disease Data Initiative. All data generated through the initiative will be made freely available to the global research community. The next phase of the project will include a national data challenge inviting the broader research community to develop and test new analytical methods using this resource.